

Date: November 8, 2024

To,
BSE Ltd.
P.J. Towers,
Dalal Street,
Mumbai-400001

Scrip Code: 524444

Sub:- Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we would like to inform you that, Evexia Lifecare Limited ("Evexia") has executed Term sheet with Diponed Research International Private Limited ("Diponed") on 08.11.2024 for its intention to subscribe on preferential basis 18,600 ("Subscription Shares") fresh fully paid up equity shares each having a face value of INR. 10 (ten), for an aggregate subscription amount of INR. 1,86,000/- (One Lakh Eighty Six Thousand only) ("Subscription Amount").

Upon completion of the issuance and allotment of the Subscription Shares, the Evexia shall hold 65% of the post issue share capital of the Company and the existing Shareholders of Diponed will hold 35% (thirty five percent) of the post issue share capital.

Further, Evexia would also provide Rs. 15.00 crores to fund the Business of the Company. The said amount shall be provided in the form of quasi capital, without interest ("Quasi Capital") in tranches.

Furthermore, Evexia can opt to convert part of the Quasi Capital, into Equity to maintain its 65% shareholding in the Company.

Also, The Board of Diponed shall consist of 6 (six) Directors including 1 (one) independent director. The existing Shareholders shall nominate 2 (two) Directors, and Evexia shall nominate 3 (three) Directors.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above acquisition is given in Annexure enclosed herewith.

Kindly take the same on your records and oblige.

Yours faithfully,

For Evexia Lifecare Limited

JAYESHBHAI R. THAKKAR
MANAGING DIRECTOR
DIN: 01631093

Annexure A

Disclosure pursuant to Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No.	Details of events that need to be provided	Information of such event(s)
1.	Name of the target entity, details in brief such as size, turnover etc.	Diponed Research International Private Limited (The Target Company)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	This is not a Related Party transaction. The Promoters/ Promoter Group doesn’t have any interest in the entity being acquired
3.	Industry to which the entity being acquired belongs	Drug discovery and development, formulations, Contract Research Services
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Target Company is engaged in the area of Drug discovery and development, formulations, Contract Research Services and Evexia, which is also engaged in the business of Pharmaceuticals is exploring various opportunity of expansion in the various field of pharmaceuticals either by way of establishment of new facility and/or acquisition of any existing company engaged in the area of pharmaceuticals and hence the object of acquiring 65% shareholding in the Target Company is based on the said policy of expansion of business of Evexia. The Evexia will also fund the funding requirement of the target Company by way of advancing Quasi Capital upto Rs.15.00Crores, in tranches, as and when required by the Target Company to meet it’s business projections.

5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable				
6.	Indicative time period for completion of the acquisition	<ul style="list-style-type: none"> Subscription amount:- (i.e. Rs. 1.86 lakhs):- within 60 days from the date of fulfillment of all the conditions precedent which will be defined in the Definitive Agreement. Quasi Capital (Upto Rs.15.00 crores) shall be provided in tranches as and when required. 				
7.	Nature of consideration – whether cash consideration or share swap and details of the same;	Cash for Fresh Equity Subscription and also towards advances having nature of Quasi Capital.				
8.	Cost of acquisition or the price at which the shares are acquired;	Rs.10/- per equity share				
9.	Percentage of shareholding/ control acquired and/or number of shares acquired;	65% of post issue share capital				
10.	Brief background about the entity acquired in terms of: <ul style="list-style-type: none"> line of business acquired: products/Service date of incorporation: history of last 3 years' turnover: 	Drug discovery and development, formulations, Contract Research Services Research Services 01/06/2022 (Rs. In thousands) <table border="1" data-bbox="986 1592 1337 1713"> <thead> <tr> <th>2023-24</th> <th>2022-23</th> </tr> </thead> <tbody> <tr> <td>16.57</td> <td>1293.94</td> </tr> </tbody> </table> (The target company was incorporated in FY 2022-23 and hence the history of turnover is provided for 2 years)	2023-24	2022-23	16.57	1293.94
2023-24	2022-23					
16.57	1293.94					

